Login to Your Account

Financings NEWS

Rain Therapeutics Inc., a startup planning a phase II test of an experimental small-molecule drug for people with EGFR and ErbB exon 20 insertion mutations in non-small-cell lung cancer, has closed a tranched $18.4 million series A round. The financing was led by Biotechnology Value Fund (BVF) and followed by Perceptive Advisors, Auckland Uniservices Ltd.'s Inventors Fund and other private investors. The series A round follows a $1 million convertible note financing the company completed in late-2017.

Accent Therapeutics Inc.formally launched with a $40 million series A and a platform built around epitranscriptomics – the field referring to RNA-modifying proteins (RMPs) that control many aspects of RNA biology – to pursue precision cancer therapies.

Onconano Medicine Inc.'s $11.7 million in series A money should let the company finish phase I trials with its imaging agent and bring a therapeutic candidate to IND-enabling studies, CEO Ravi Srinivasan told BioWorld, as the company works with a "phenomenon [that] has not been exploited so far, even though it's been well-known and well-established in the cancer field."

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: